Antibrain antibodies in multiple sclerosis. Relation to clinical variables

Area of Science:

• Neuroimmunology
• Neurology

Background:

• Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS).
• The role of specific autoantibodies in MS pathogenesis is an area of ongoing research.

Purpose of the Study:

• To investigate the presence and significance of IgG antibrain antibodies (ABA) in patients with MS.
• To correlate ABA levels with clinical parameters and disease course in MS.

Main Methods:

• Complement fixation technique used to detect and titrate IgG ABA in paired serum and cerebrospinal fluid (CSF) samples.
• Analysis included patients with clinically definite MS, probable MS, other neurological diseases, and healthy controls.
• Correlation of ABA titres with age, disease onset, disease severity, and routine CSF variables.

Main Results:

• IgG ABA were detected in 40% of sera and 88% of CSF samples from patients with clinically definite MS.
• Higher prevalence and titres of ABA were observed in MS patients compared to controls.
• ABA titres in both serum and CSF correlated with a more malignant disease course and were higher in younger patients with earlier disease onset.

Conclusions:

• Complement-fixing IgG ABA are frequently present in MS patients, particularly in CSF.
• These antibodies may play a pathogenic role in MS through various mechanisms, including complement activation and cell-mediated cytotoxicity.
• ABA titres serve as a potential biomarker for disease activity and severity in multiple sclerosis.